Anti-GD2 chimeric antigen receptor T cell therapy - Bellicum Pharmaceuticals

Drug Profile

Anti-GD2 chimeric antigen receptor T cell therapy - Bellicum Pharmaceuticals

Alternative Names: Anti-GD2 CAR transduced T cells - Bellicum Pharmaceuticals; Anti-GD2 CIDeCAR T cell therapy - Bellicum Pharmaceuticals; Anti-GD2 third party CAR T cell therapy - Bellicum Pharmaceuticals; GD2-CAR.OX40.28.z.ICD9

Latest Information Update: 17 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bellicum Pharmaceuticals
  • Developer National Cancer Institute (USA)
  • Class Antineoplastics; CAR-T cell therapies; Cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
  • 31 Jan 2017 National Cancer Institute completes a phase I trial in Solid tumours (Second-line therapy or greater, Recurrent, Metastatic disease, In children, In adolescents, In adults) in USA (IV) (NCT02107963)
  • 01 Nov 2016 Bellicum and Ospedale Pediatrico Bambino Gesù collaborate on the development of CAR T-cell therapies and TCR cell therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top